<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631773</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx162.140</article-id><article-id pub-id-type="publisher-id">ofx162.140</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Oral Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heineman</surname><given-names>Thomas C</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Bernstein</surname><given-names>David</given-names></name><degrees>MD, FIDSA</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Wald</surname><given-names>Anna</given-names></name><degrees>MD, MPH, FIDSA</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Van Wagoner</surname><given-names>Nicholas</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Leone</surname><given-names>Peter</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Mayer</surname><given-names>Kenneth</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Lucksinger</surname><given-names>Gregg</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Win</surname><given-names>Sandra</given-names></name><degrees>MD, MS</degrees><xref ref-type="aff" rid="AF0008">8</xref></contrib><contrib contrib-type="author"><name><surname>Koltun</surname><given-names>William</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0009">9</xref></contrib><contrib contrib-type="author"><name><surname>Desai</surname><given-names>Nisha</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Oliphant</surname><given-names>Thomas</given-names></name><degrees>MS, PhD</degrees><xref ref-type="aff" rid="AF0011">11</xref></contrib><contrib contrib-type="author"><name><surname>Natenshon</surname><given-names>Andrew</given-names></name><degrees>MA</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>McNeil</surname><given-names>Lisa K</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Flechtner</surname><given-names>Jessica B</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Hetherington</surname><given-names>Seth</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Genocea Biosciences</institution>, <addr-line>Cambridge, MA</addr-line>;</aff><aff id="AF0002">
<label>2</label>
<institution>Cincinnati Children&#x02019;s Hospital Medical Center</institution>, <addr-line>Cincinnati, Ohio</addr-line>;</aff><aff id="AF0003">
<label>3</label>
<institution>Department of Medicine, University of Washington</institution>, <addr-line>Seattle, Washington</addr-line>;</aff><aff id="AF0004">
<label>4</label>
<institution>Division of Infectious Diseases, University of Alabama at Birmingham</institution>, <addr-line>Birmingham, Alabama</addr-line>;</aff><aff id="AF0005">
<label>5</label>
<institution>Department of Medicine, University of North Carolina</institution>, <addr-line>Chapel Hill, North Carolina</addr-line>;</aff><aff id="AF0006">
<label>6</label>
<institution>The Fenway Institute</institution>, <addr-line>Boston, Massachusetts</addr-line>;</aff><aff id="AF0007">
<label>7</label>
<institution>Tekton Research</institution>, <addr-line>Austin, Texas</addr-line>;</aff><aff id="AF0008">
<label>8</label>
<institution>eStudy Site</institution>, <addr-line>San Francisco, California</addr-line>;</aff><aff id="AF0009">
<label>9</label>
<institution>Medical Center for Clinical Research</institution>, <addr-line>San Diego, California</addr-line>;</aff><aff id="AF0010">
<label>10</label>
<institution>Flanders Center</institution>, <addr-line>Portland, Oregon</addr-line>;</aff><aff id="AF0011">
<label>11</label>
<institution>Innovative Analytics</institution>, <addr-line>Kalamazoo, Michigan</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 229. Miscellaneous Advances in Vaccinology</p><p>
<italic>Saturday, October 7, 2017: 10:30 AM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S59</fpage><lpage>S59</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx162.140.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>GEN-003 is an investigational genital herpes immunotherapy comprising gD2&#x00394;TMR, an HSV-2 antigen that induces neutralizing antibody and T cell responses, ICP4.2, an HSV-2 T cell antigen selected through human T cell screens, and Matrix-M2&#x02122;, a saponin-based adjuvant. This Phase 2b study was designed to evaluate efficacy and safety of GEN-003 vs. placebo.</p></sec><sec id="s2"><title>Methods</title><p>Healthy persons, age 18&#x02013;50&#x000a0;years, with 3&#x02013;9 HSV-2 genital herpes outbreaks annually were randomized to 3 groups: placebo, or 60&#x000a0;&#x000b5;g of each antigen combined with 50&#x000a0;&#x000b5;g (60/50 group) or 75&#x000a0;&#x000b5;g (60/75 group) of adjuvant, administered 3 times 21&#x000a0;days apart. Study endpoints included safety, immunogenicity, HSV-2 shedding frequency, lesion rate and recurrence frequency. Viral shedding was measured from anogenital swabs by PCR. Swabs were collected for 28&#x000a0;days at baseline, and after the third dose, 6&#x000a0;months and 1&#x000a0;year. The presence of herpes lesions was recorded daily by electronic&#x000a0;diary.</p></sec><sec id="s3"><title>Results</title><p>One hundred and thirty-one participants enrolled and &#x0003e;90% received all 3 doses. In the 28-day post-treatment period, viral shedding was reduced by 40% and 27% in the 60/50 and 60/75 groups, respectively, compared with a 5% increase in the placebo group. At 6&#x000a0;months post-treatment, median lesion rates were significantly lower in the 60/50 and 60/75 groups (2.7% and 1.9%, respectively) vs. the placebo group (5.6%, p &#x0003c; 0.05), resulting in median reductions of 52% and 66%. In participants not receiving suppressive antivirals, the median recurrence frequency was 1.0/6&#x000a0;months in the 60/50 group vs. 2.0 in the placebo group (p&#x000a0;=&#x000a0;0.08). The median recurrence duration in the 60/50 group was lower than in the placebo group (2.8 vs. 4.2&#x000a0;days; p &#x0003c; 0.05). The most commonly reported adverse events (AEs) following GEN-003 vaccination were injection site pain/tenderness (97%), fatigue (82%), headache (82%) and myalgia (80%). No vaccine-related serious AEs, autoimmune events or other AEs of special interest were reported.</p></sec><sec id="s4"><title>Conclusion</title><p>In adults with recurrent genital herpes, GEN-003 reduced HSV-2 shedding frequency, genital herpes lesion rate, recurrence frequency and recurrence duration through 6&#x000a0;months after the last dose. Local and systemic symptoms were common in GEN-003 recipients, but treatment completion was high with few discontinuations due to AEs.</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>T.&#x000a0;C. Heineman</bold>, GSK group of companies: Consultant and Shareholder, Consulting fee; <bold>D. Bernstein</bold>, Genocea Biosciences: Consultant and Investigator, Consulting fee and Research support; <bold>A. Wald</bold>, Genocea Biosciences: Investigator, Research grant and Support for travel to meetings for the study; <bold>N. Van Wagoner</bold>, Genocea Biosciences: Consultant, Research support and Travel support to present at scientific meetings; <bold>P. Leone</bold>, Genocea Biosciences: Grant Investigator and Scientific Advisor, Consulting fee, Research grant and Speaker honorarium; &#x02028;<bold>T. Oliphant</bold>, Genocea Biosciences: Consultant, Consulting fee; <bold>A. Natenshon</bold>, Genocea Biosciences: Employee, Salary; <bold>L. K.&#x000a0;McNeil</bold>, Genocea Biosciences: Employee, Salary; <bold>J. B.&#x000a0;Flechtner</bold>, Genocea Biosciences: Employee, Salary; <bold>S. Hetherington</bold>, Genocea Biosciences: Employee, Salary</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>